Clinical Trial Update: Randomized Phase II Study to Assess PD 0332991 in Breast Cancer [Phase 2]

View source ↗

Summary

A randomized Phase II study assessed PD-0332991 (palbociclib) in untreated operable early breast cancer. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Untreated Operable Early Breast Cancer | Phase 2 | Status: COMPLETED